Anna Suk Fong Lok

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. doi request reprint Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders
    Anna S Lok
    Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA Electronic address
    J Hepatol 60:490-9. 2014
  2. ncbi request reprint Evolution of nucleoside/tide analogues for hepatitis B: is the ideal drug here yet?
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Health System, 3912 Taubman Center, SPC 5362, Ann Arbor, MI 48109, USA
    J Hepatol 51:416-8. 2009
  3. ncbi request reprint Long-term safety of lamivudine treatment in patients with chronic hepatitis B
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, 48109 0362, USA
    Gastroenterology 125:1714-22. 2003
  4. pmc Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial
    Anna S Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    Hepatology 49:1828-37. 2009
  5. doi request reprint Preliminary study of two antiviral agents for hepatitis C genotype 1
    Anna S Lok
    Department of Internal Medicine, Division of Gastroenterology, 3912 Taubman Center, SPC 5362, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    N Engl J Med 366:216-24. 2012
  6. doi request reprint Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma?
    Anna Suk Fong Lok
    University of Michigan, Ann Arbor, Michigan 48109, USA
    J Gastroenterol Hepatol 26:221-7. 2011
  7. doi request reprint How to diagnose and treat hepatitis B virus antiviral drug resistance in the liver transplant setting
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Hospitals, Ann Arbor, Michigan 48109, USA
    Liver Transpl 14:S8-S14. 2008
  8. pmc Outcome of sustained virological responders with histologically advanced chronic hepatitis C
    Timothy R Morgan
    Division of Gastroenterology, University of California Irvine, Irvine, CA, USA
    Hepatology 52:833-44. 2010
  9. pmc Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list
    Melissa K Osborn
    University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA
    Clin Gastroenterol Hepatol 5:1454-61. 2007
  10. ncbi request reprint Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation
    Scott K Fung
    Division of Gastroenterology, University of Michigan, Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109 0362, USA
    J Hepatol 43:937-43. 2005

Detail Information

Publications86

  1. doi request reprint Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders
    Anna S Lok
    Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA Electronic address
    J Hepatol 60:490-9. 2014
    ..We evaluated daclatasvir plus once- or twice-daily asunaprevir in non-cirrhotic genotype 1 null responders...
  2. ncbi request reprint Evolution of nucleoside/tide analogues for hepatitis B: is the ideal drug here yet?
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Health System, 3912 Taubman Center, SPC 5362, Ann Arbor, MI 48109, USA
    J Hepatol 51:416-8. 2009
  3. ncbi request reprint Long-term safety of lamivudine treatment in patients with chronic hepatitis B
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, 48109 0362, USA
    Gastroenterology 125:1714-22. 2003
    ..The aim of this analysis was to determine the incidence of hepatitis flares, hepatic decompensation, and liver-disease-related (LDR) serious adverse events (SAE) during long-term lamivudine treatment...
  4. pmc Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial
    Anna S Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    Hepatology 49:1828-37. 2009
    ....
  5. doi request reprint Preliminary study of two antiviral agents for hepatitis C genotype 1
    Anna S Lok
    Department of Internal Medicine, Division of Gastroenterology, 3912 Taubman Center, SPC 5362, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    N Engl J Med 366:216-24. 2012
    ..Patients with chronic hepatitis C virus (HCV) infection who have not had a response to therapy with peginterferon and ribavirin may benefit from the addition of multiple direct-acting antiviral agents to their treatment regimen...
  6. doi request reprint Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma?
    Anna Suk Fong Lok
    University of Michigan, Ann Arbor, Michigan 48109, USA
    J Gastroenterol Hepatol 26:221-7. 2011
    ..Safer, more effective, and more affordable antiviral therapies are needed for both hepatitis B and hepatitis C so more patients can benefit from treatment and more HCCs can be prevented...
  7. doi request reprint How to diagnose and treat hepatitis B virus antiviral drug resistance in the liver transplant setting
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Hospitals, Ann Arbor, Michigan 48109, USA
    Liver Transpl 14:S8-S14. 2008
    ..Occurrence of antiviral drug resistance can be reduced by the use of the most potent nucleos(t)ide analogue(s) with the highest genetic barrier to resistance, emphasis of medication compliance, and close monitoring of virologic response...
  8. pmc Outcome of sustained virological responders with histologically advanced chronic hepatitis C
    Timothy R Morgan
    Division of Gastroenterology, University of California Irvine, Irvine, CA, USA
    Hepatology 52:833-44. 2010
    ..15, 95% CI = 0.06-0.38) or HCC (HR = 0.19, 95% CI = 0.04-0.80) was significant for SVR compared to NR. Laboratory tests related to liver disease severity improved following SVR...
  9. pmc Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list
    Melissa K Osborn
    University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA
    Clin Gastroenterol Hepatol 5:1454-61. 2007
    ..Use of antiviral salvage therapy might decrease this risk...
  10. ncbi request reprint Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation
    Scott K Fung
    Division of Gastroenterology, University of Michigan, Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109 0362, USA
    J Hepatol 43:937-43. 2005
    ..The aim of this study was to describe the clinical course of patients with adefovir-resistant HBV infection...
  11. doi request reprint Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations
    Jessica Tan
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI 48109 0362, USA
    J Hepatol 48:391-8. 2008
    ..We sought to identify mutations associated with treatment failure to adefovir (ADV) and to determine virologic response to tenofovir (TDF) alone and in combination with emtricitabine (FTC) in these patients...
  12. ncbi request reprint Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy
    Stephen N Wong
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109 0362, USA
    Liver Transpl 13:374-81. 2007
    ..Maintenance therapy with NA after discontinuation of long-term HBIG therapy is associated with a low risk of HBV recurrence after OLT in compliant HBV patients...
  13. ncbi request reprint Treatment of chronic hepatitis B: who to treat, what to use, and for how long?
    Scott K Fung
    Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan 48109 0362, USA
    Clin Gastroenterol Hepatol 2:839-48. 2004
    ..Duration of treatment is at least 1 year with lamivudine and adefovir; longer duration of treatment is needed in most patients, but the optimal duration of treatment and the criteria for stopping treatment have not been established...
  14. pmc Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C
    Robert J Fontana
    Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan, USA
    Am J Gastroenterol 103:2766-75. 2008
    ..The aim of this study was to identify baseline and on-treatment predictors of depression in CHC patients receiving peginterferon and ribavirin...
  15. ncbi request reprint Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma
    Stephen N Wong
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109 0362, USA
    Liver Transpl 13:334-42. 2007
    ..In conclusion, despite more advanced liver disease and a lower rate of transplantation, ITT survival of patients listed for HBV-cirrhosis was comparable to those with HBV-HCC, possibly related to beneficial effects of antiviral therapy...
  16. ncbi request reprint Virologic response and resistance to adefovir in patients with chronic hepatitis B
    Scott K Fung
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109 0362, USA
    J Hepatol 44:283-90. 2006
    ..The incidence and risk factors for adefovir-resistant HBV have not been clearly defined...
  17. ncbi request reprint Emotional distress during interferon-alpha-2B and ribavirin treatment of chronic hepatitis C
    Robert J Fontana
    Department of Internal Medicine and the Consortium for Health Outcomes Innovation and Cost Effectiveness Studies, University of Michigan Medical School, Ann Arbor, MI 48109 0362, USA
    Psychosomatics 43:378-85. 2002
    ..Because of its brevity and simplicity, the Brief Symptom Inventory may prove to be a useful adjunct to clinician assessment in detecting and monitoring emotional distress during interferon-alpha treatment of chronic hepatitis C...
  18. pmc Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir
    Munira Hussain
    Division of Gastroenterology, University of Michigan Medical Center, 1500 East Medical Center Drive, 3912 Taubman Center, Box 0362, Ann Arbor, Michigan 48109 0362, USA
    J Clin Microbiol 44:1094-7. 2006
    ..Our study confirms that this assay can simultaneously detect the presence of lamivudine and adefovir resistance mutations in clinical samples, has a high degree of concordance with sequencing, and can detect mutants earlier...
  19. ncbi request reprint Effectiveness of interferon alpha-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice
    Thomas M Shehab
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, USA
    Clin Gastroenterol Hepatol 2:425-31. 2004
    ....
  20. ncbi request reprint Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B
    Robert J Fontana
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, USA
    Liver Transpl 8:433-9. 2002
    ....
  21. pmc Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation
    Norah A Terrault
    Department of Medicine, Division of Gastroenterology, University of California at San Francisco, San Francisco, CA, USA
    Liver Transpl 13:122-9. 2007
    ..Important predictors of graft loss in HCV-infected patients were limited LDLT experience, pretransplant HCC, and higher MELD at transplantation...
  22. doi request reprint Re-weighting the model for end-stage liver disease score components
    Pratima Sharma
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA
    Gastroenterology 135:1575-81. 2008
    ..We re-estimated MELD coefficients and evaluated the effect of updated MELD on the liver transplant waiting list ranking...
  23. ncbi request reprint HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C
    Chun Tao Wai
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA
    Hepatology 36:1425-30. 2002
    ..Stratification for HBV genotypes should be considered in future clinical trials of antiviral therapy of chronic hepatitis B...
  24. ncbi request reprint Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005
    Hyung Joon Yim
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109 0362, USA
    Hepatology 43:S173-81. 2006
    ..Newer antiviral therapies with improved efficacy and decreased risk of resistance may lead to a complete revision of the chapter on the natural history of chronic HBV infection on the occasion of the golden jubilee of Hepatology...
  25. ncbi request reprint Navigating the maze of hepatitis B treatments
    Anna Suk Fong Lok
    Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan 48109, USA
    Gastroenterology 132:1586-94. 2007
  26. doi request reprint Antiviral therapy for chronic hepatitis B
    Syed Mohammed R Jafri
    University of Michigan Health System, Ann Arbor, 48109, USA
    Clin Liver Dis 14:425-38. 2010
    ..These therapies are effective in suppressing HBV replication and have also been shown to prevent disease progression...
  27. ncbi request reprint Chronic hepatitis B
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Box 0362, Ann Arbor, MI 48109 0362, USA
    Hepatology 45:507-39. 2007
  28. ncbi request reprint Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48210, USA
    Hepatology 42:282-92. 2005
    ..In conclusion, a model based on standard laboratory test results can be used to predict histological cirrhosis with a high degree of accuracy in 50% of patients with CHC...
  29. ncbi request reprint Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C
    Robert J Fontana
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109 0362, USA
    Hepatology 45:1154-63. 2007
    ..Nonetheless, the frequency of cognitive impairment did not increase during the first 24 weeks of treatment in 177 patients (34% versus 32%, P=0.64) nor in the 57 patients completing 48 weeks of treatment (P=0.48, ANOVA)...
  30. ncbi request reprint Cognitive reserve and neuropsychological functioning in patients infected with hepatitis C
    Linas A Bieliauskas
    Neuropsychology Section, Department of Psychiatry, University of Michigan Medical Center, Ann Arbor, Michigan 48105, USA
    J Int Neuropsychol Soc 13:687-92. 2007
    ..It is important to account for CRS when assessing cognitive findings in large-scale clinical trials...
  31. ncbi request reprint High-dose interferon alfa-2b and ribavirin in patients previously treated with interferon: results of a prospective, randomized, controlled trial
    Robert J Fontana
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA
    J Clin Gastroenterol 34:177-82. 2002
    ..Kinetic studies have demonstrated a more rapid reduction in hepatitis C virus (HCV) RNA levels among patients taking high daily doses of interferon compared with those taking standard-dose interferon...
  32. pmc Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    J Clin Microbiol 40:3729-34. 2002
    ....
  33. ncbi request reprint Prevention of recurrent hepatitis B post-liver transplantation
    Anna S F Lok
    University of Michigan, Ann Arbor, MI, USA
    Liver Transpl 8:S67-73. 2002
    ..6. Lamivudine resistance before LT is associated with an increased risk for recurrent hepatitis B post-LT. 7. A cost-effective prophylactic regimen to prevent recurrent hepatitis B should be tailored according to risk...
  34. pmc Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C
    Robert J Fontana
    Department of Internal Medicine, University of Michigan, 3912 Taubman Center, Ann Arbor, Michigan, USA
    Gut 59:1401-9. 2010
    ..The aim of this study was to explore the association of serum fibrosis marker levels with the risk of clinical and histological disease progression in a large cohort of patients with chronic hepatitis C (CHC)...
  35. ncbi request reprint Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0362, USA
    Clin Gastroenterol Hepatol 5:245-54. 2007
    ....
  36. ncbi request reprint Chronic hepatitis B
    Anna S F Lok
    University of Michigan, Ann Arbor, MI 48109, USA
    N Engl J Med 346:1682-3. 2002
  37. doi request reprint Public health impact of antiviral therapy for hepatitis C in the United States
    Michael L Volk
    Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI 48109, USA
    Hepatology 50:1750-5. 2009
    ..Results from the NHANES questionnaire suggest that the primary barrier to treatment is lack of diagnosis, with 69/133 (adjusted proportion 49%) of respondents previously unaware that they had hepatitis C...
  38. ncbi request reprint Emotional distress in chronic hepatitis C patients not receiving antiviral therapy
    Robert J Fontana
    Department of Internal Medicine, Division of Gastroenterology, University of Michigan Medical School, 3912 Taubman Center, Ann Arbor, MI 48109 0362, USA
    J Hepatol 36:401-7. 2002
    ..The aim of our study was to determine the prevalence, type, and severity of emotional distress in a large group of consecutive chronic hepatitis C (CHC) patients not receiving anti-viral therapy...
  39. pmc Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis
    Robert J Fontana
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0362, USA
    Clin Gastroenterol Hepatol 7:219-26. 2009
    ..Serum fibrosis marker levels during the lead-in treatment phase of patients enrolled in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial were determined...
  40. ncbi request reprint Impact of the model for end-stage liver disease allocation policy on the use of high-risk organs for liver transplantation
    Michael L Volk
    Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan 48109, USA
    Gastroenterology 135:1568-74. 2008
    ..We aimed to determine whether implementation of MELD affected the quality of organs transplanted, the type of patients who receive the higher-risk organs, and the impact of these changes on their posttransplant survival...
  41. ncbi request reprint Chronic hepatitis B: update of recommendations
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109 0362, USA
    Hepatology 39:857-61. 2004
  42. ncbi request reprint Newer markers for hepatocellular carcinoma
    Jorge A Marrero
    Division of Gastroenterology, University of Michigan, 3912 Taubman Center, Ann Arbor, Michigan 48109 0362, USA
    Gastroenterology 127:S113-9. 2004
    ..There is an urgent need for novel biomarkers for the detection of early HCC; the National Cancer Institute proposal provides a framework for future validation studies...
  43. ncbi request reprint Prevention of hepatitis B virus-related hepatocellular carcinoma
    Anna S F Lok
    of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109 0362, USA
    Gastroenterology 127:S303-9. 2004
    ..In addition, questions on who to treat and how long treatment should be administered must be addressed before recommendations on the use of antiviral therapy to prevent HBV-related HCC can be made...
  44. ncbi request reprint Management of chronic hepatitis B
    Hari S Conjeevaram
    Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109 0362, USA
    J Hepatol 38:S90-103. 2003
  45. doi request reprint Beyond utilitarianism: a method for analyzing competing ethical principles in a decision analysis of liver transplantation
    Michael L Volk
    Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan 48109, USA
    Med Decis Making 28:763-72. 2008
    ..In this study, the authors examine a method to incorporate competing ethical principles in a decision analysis of liver transplantation for a patient with acute liver failure (ALF)...
  46. doi request reprint Hepatitis B virus variants
    Watcharasak Chotiyaputta
    Division of Gastroenterology, University of Michigan Health System, Ann Arbor, MI, USA
    Nat Rev Gastroenterol Hepatol 6:453-62. 2009
    ....
  47. ncbi request reprint Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantation
    Munira Hussain
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI 48109 0362, USA
    Liver Transpl 13:1137-44. 2007
    ..Our findings suggest that occult HBV reinfection occurs in most HBV patients after OLT and continued administration of appropriate prophylactic therapy is important in preventing overt HBV recurrence...
  48. ncbi request reprint Update on viral hepatitis: 2005
    Stephen N Wong
    Division of Gastroenterology, University of Michigan Medical School, Ann Arbor, 48109, USA
    Curr Opin Gastroenterol 22:241-7. 2006
    ..This review aims to provide a concise summary of relevant developments in the treatment and prevention of viral hepatitis based on publications between December 2004 and November 2005...
  49. ncbi request reprint Management of hepatitis B patients with antiviral resistance
    Scott K Fung
    Division of Gastroenterology, University of Michigan, Ann Arbor, Mich, USA
    Antivir Ther 9:1013-26. 2004
    ..The ideal approach is to prevent antiviral resistance through judicious use of antiviral therapy and the use of more potent antiviral agents, possibly in combination...
  50. ncbi request reprint Update on viral hepatitis in 2004
    Scott K Fung
    Division of Gastroenterology, University of Michigan, Ann Arbor, 48109, USA
    Curr Opin Gastroenterol 21:300-7. 2005
    ..Studies reporting novel and clinically relevant findings were selected after a PubMed search. The aim is to provide an up-to-date summary of important developments in viral hepatitis...
  51. ncbi request reprint Natural history of hepatitis B and outcomes after liver transplantation
    Mary Ann Huang
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109, USA
    Clin Liver Dis 7:521-36. 2003
    ....
  52. ncbi request reprint Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection
    Chi Jen Chu
    Department of Medicine, Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI, USA
    Hepatology 36:1408-15. 2002
    ..Given the fluctuating course of HBeAg-negative chronic hepatitis, it is not possible to define a single cutoff HBV DNA value for differentiating inactive carriers from patients with HBeAg-negative chronic hepatitis...
  53. ncbi request reprint Treatment of hepatitis B
    Chun Tao Wai
    Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Box 0362, Ann Arbor, MI 48109 0362, USA
    J Gastroenterol 37:771-8. 2002
    ..This review updates safety and efficacy data of interferon alpha and lamivudine in the treatment of chronic hepatitis B. Management strategies in different clinical scenarios and future treatments are also discussed...
  54. ncbi request reprint Noninvasive monitoring of patients with chronic hepatitis C
    Robert J Fontana
    Division of Gastroenterology, University of Michigan Health System, Ann Arbor, MI, USA
    Hepatology 36:S57-64. 2002
    ..There is an urgent need to develop and validate noninvasive tests that can accurately reflect the full spectrum of hepatic inflammation and fibrosis in chronic hepatitis C...
  55. ncbi request reprint Management of patients with hepatitis B virus-induced cirrhosis
    Scott K Fung
    Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109 0362, USA
    J Hepatol 42:S54-64. 2005
  56. ncbi request reprint Drug insight: Nucleoside and nucleotide analog inhibitors for hepatitis B
    Scott K Fung
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI 48109 0362, USA
    Nat Clin Pract Gastroenterol Hepatol 1:90-7. 2004
    ..Several other nucleoside and nucleotide analogs are being evaluated in phase II/III clinical trials for hepatitis B...
  57. doi request reprint Indications for therapy in hepatitis B
    Bulent Degertekin
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109, USA
    Hepatology 49:S129-37. 2009
    ..All patients who are not initiated on treatment should continue to be monitored so treatment can be started if and when the indication arises...
  58. ncbi request reprint Evolution of multi-drug resistant hepatitis B virus during sequential therapy
    Hyung Joon Yim
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109 0362, USA
    Hepatology 44:703-12. 2006
    ..De novo combination therapy may prevent the emergence of multi-drug resistant mutants...
  59. ncbi request reprint Prevalence of HBV precore/core promoter variants in the United States
    Chi Jen Chu
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA
    Hepatology 38:619-28. 2003
    ..Physicians should be aware of the existence of HBV precore and core promoter variants and the clinical condition of "HBeAg-negative chronic hepatitis."..
  60. pmc Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants
    Munira Hussain
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0362, USA
    J Clin Microbiol 41:3699-705. 2003
    ..INNO-LiPA is rapid, sensitive, and reliable-thus enabling accurate determination of HBV genotypes and detection of PC and CP variants in a large population of patients...
  61. ncbi request reprint Hepatitis B virus genotypes in the United States: results of a nationwide study
    Chi Jen Chu
    Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Box 0362, Ann Arbor, Michigan 48109 0362, USA
    Gastroenterology 125:444-51. 2003
    ..The aims of this nationwide study were to determine the prevalence of HBV genotypes in the United States and the association between HBV genotypes and patient demographics, mode of infection, and clinical status...
  62. pmc A genotype-independent real-time PCR assay for quantification of hepatitis B virus DNA
    Ying Liu
    Division of Gastroenterology, University of Michigan Medical Center, 1500 East Medical Center Dr, 3912 Taubman Center, Box 0362, Ann Arbor, MI 48109 0362, USA
    J Clin Microbiol 45:553-8. 2007
    ..We have established a real-time PCR assay that is genotype independent and can accurately quantify a wide range of HBV DNA levels. Further studies of additional samples are ongoing to validate the genotype independence of our assay...
  63. ncbi request reprint Hepatitis B: progress in the last decade
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, USA
    Semin Liver Dis 23:1-4. 2003
  64. ncbi request reprint Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C
    Chi Jen Chu
    Division of Gastroenterology, Department of Medicine, University of Michigan and VA Medical Center, Ann Arbor, Michigan, USA
    Gastroenterology 122:1756-62. 2002
    ..The aim of our study was to determine if HBV genotype B is associated with higher rates of spontaneous hepatitis B e antigen (HBeAg) seroconversion compared with genotype C...
  65. ncbi request reprint Identification and management of hepatitis C patients in primary care clinics
    Thomas M Shehab
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan 48109, USA
    Am J Gastroenterol 98:639-44. 2003
    ..Previous survey-based research suggested that hepatitis C patients receive suboptimal care in primary care settings. The aim of our study was to define the actual level of care hepatitis C patients receive in primary care clinics...
  66. doi request reprint Update on viral hepatitis: 2008
    Bulent Degertekin
    Division of Gastroenterology, University of Michigan Health System, Ann Arbor, Michigan 48109, USA
    Curr Opin Gastroenterol 25:180-5. 2009
    ..The present review is a concise review of recent developments in the field of viral hepatitis, based on publications between December 2007 and November 2008...
  67. ncbi request reprint Combination of HBIG and lamivudine-resistant mutations: a formula for trouble?
    Robert J Fontana
    Division of Gastroenterology University of Michigan Medical School Ann Arbor, MI, USA
    Liver Transpl 8:1082-4. 2002
  68. ncbi request reprint Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status
    Adrian M Di Bisceglie
    Department of Internal Medicine, Saint Louis University School of Medicine, St Louis, Missouri 63110, USA
    Am J Gastroenterol 98:2060-3. 2003
    ..The aim of this study was to evaluate the influence of racial and ethnic status in the viral etiology of HCC in the US...
  69. ncbi request reprint Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial
    Gregory T Everson
    Section of Hepatology, Division of Gastroenterology and Hepatology, University of Colorado School of Medicine, Denver, CO, USA
    Hepatology 44:1675-84. 2006
    ..In conclusion, disease severity is a major independent determinant of rate of SVR in patients with advanced chronic hepatitis C. New strategies are needed to optimize antiviral therapy in these "difficult-to-cure" patients...
  70. ncbi request reprint Occult hepatitis B virus infection in patients with hepatocellular carcinoma: Innocent bystander, cofactor, or culprit?
    Jorge A Marrero
    Gastroenterology 126:347-50. 2004
  71. doi request reprint Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C
    Karen L Lindsay
    Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
    Clin Gastroenterol Hepatol 6:234-41. 2008
    ..Although viral kinetic profiles in treatment responders shed light on the mechanism of action of interferon and ribavirin, minimal information is available to explain why some patients experience little or no virologic suppression...
  72. ncbi request reprint Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    Gastroenterology 132:103-12. 2007
    ..However, prior studies did not assess the impact of reducing the dose of peginterferon independent of ribavirin or differentiate between dose reduction or interrupting or prematurely discontinuing treatment...
  73. ncbi request reprint HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial
    Chihiro Morishima
    Department of Laboratory Medicine, University of Washington, Seattle, WA 98104, USA
    Hepatology 44:360-7. 2006
    ..In patients with negative PCR results during treatment, a single positive TMA test did not exclude SVR, although persistently positive tests did...
  74. ncbi request reprint Tenofovir disoproxil fumarate: role in hepatitis B treatment
    Stephen N Wong
    Hepatology 44:309-13. 2006
  75. ncbi request reprint Antiviral therapy for pre- and post-liver transplantation patients with hepatitis B
    Jessica Tan
    Liver Transpl 13:323-6. 2007
  76. ncbi request reprint Management of hepatitis B: summary of a clinical research workshop
    Jay H Hoofnagle
    Liver Disease Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
    Hepatology 45:1056-75. 2007
    ..Clearly, many basic and clinical research challenges remain in defining optimal means of management of chronic hepatitis B...
  77. ncbi request reprint Antiviral options for the treatment of chronic hepatitis B
    Melissa K Osborn
    Division of Infectious Diseases, Emory University School of Medicine Atlanta, GA, USA
    J Antimicrob Chemother 57:1030-4. 2006
    ..Development of drug resistance is a major concern with long-term treatment. Even with successful therapy, patients remain at risk for reactivation of viral replication and require lifelong monitoring...
  78. ncbi request reprint Treatment of hepatitis B: who, when, and how?
    Stephen N Wong
    Arch Intern Med 166:9-12. 2006
  79. ncbi request reprint Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial
    Adrian M Di Bisceglie
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, 3635 Vista Avenue, St Louis, MO 63110, USA
    J Hepatol 43:434-41. 2005
    ..We assessed serum AFP among patients with chronic hepatitis C and advanced fibrosis to establish predictors of AFP elevations and changes with antiviral therapy...
  80. ncbi request reprint Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial
    Leonard B Seeff
    Division of Digestive Diseases and Nutrition, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Hepatology 47:605-12. 2008
    ..Because its use among these HALT-C participants was self-motivated and uncontrolled, however, only a well-designed prospective study can determine whether silymarin provides benefit to persons with chronic hepatitis C...
  81. ncbi request reprint Liver transplantation for patients with lamivudine-resistant HBV: what is the optimal prophylactic strategy?
    Anna S F Lok
    Liver Transpl 11:490-3. 2005
  82. doi request reprint Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C
    Kirti Shetty
    Division of Transplantation, Georgetown University Hospital, Washington, DC 20007, USA
    Liver Transpl 14:534-40. 2008
    ..Occult HBV infection is strongly associated with the presence of anti-HBc, history of injection drug use, and explant-proven HCC...
  83. pmc Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C
    Chihiro Morishima
    Department of Laboratory Medicine, Virology Division, University of Washington, Seattle, WA, USA
    Hepatology 48:1412-9. 2008
    ..With continued treatment, patients with inconsistently positive TMA results were more likely to become TMA-negative than TMA-positive (P < 0.0001)...
  84. ncbi request reprint When to start and stop hepatitis B treatment: can one set of criteria apply to all patients regardless of age at infection?
    Bulent Degertekin
    Ann Intern Med 147:62-4. 2007
  85. ncbi request reprint Hepatitis B virus genotypes, precore and core promoter variants among predominantly Asian patients with chronic HBV infection in a Canadian center
    Scott K Fung
    Department of Medicine, University of Toronto, Toronto, ON, Canada
    Liver Int 26:796-804. 2006
    ..The purpose of this study was to determine the prevalence of HBV genotypes, precore (PC) and core promoter (CP) variants, and the proportion of patients meeting treatment criteria for HBV...
  86. ncbi request reprint Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection?
    Scott K Fung
    Hepatology 40:790-2. 2004